Fc?RIIb expression in early stage chronic lymphocytic leukemia
Por:
Bosch R., Mora A., Vicente E.P., Ferrer G., Jansà S., Damle R., Gorlatov S., Rai K., Montserrat E., Nomdedeu J., Pratcorona M., Blanco L., Saavedra S., Garrido A., Esquirol A., Garcia I., Granell M., Martino R., Delgado J., Sierra J., Chiorazzi N., Moreno C.
Publicada:
1 ene 2017
Resumen:
In normal B-cells, B-cell antigen receptor (BCR) signaling can be negatively regulated by the low-affinity receptor Fc?RIIb (CD32b). To better understand the role of Fc?RIIb in chronic lymphocytic leukemia (CLL), we correlated its expression on 155 samples from newly-diagnosed Binet A patients with clinical characteristics and outcome. Fc?RIIb expression was similar in normal B-cells and leukemic cells, this being heterogenous among patients and within CLL clones. Fc?RIIb expression did not correlate with well known prognostic markers [disease stage, serum beta-2 microglobulin (B2M), IGHV mutational status, expression of ZAP-70 and CD38, and cytogenetics] except for a weak concordance with CD49d. Moreover, patients with low Fc?RIIb expression (69/155, 44.5%) required therapy earlier than those with high Fc?RIIb expression (86/155, 55.5%) (median 151.4 months vs. not reached; p=.071). These results encourage further investigation on the role of Fc?RIIb in CLL biology and prognostic significance in larger series of patients. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
|